GIC invests US$1b in plasma collection company Biomat
[MADRID] Singapore's wealth fund GIC agreed to invest around US$1 billion in Biomat, a US-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutical company, Grifols said on Wednesday.
GIC will have a minority stake in Biomat USA, which has a network of 296 plasma collection centres in the United States through the acquisition of newly issued non-voting shares.
The company didn't disclose the stake GIC will taking in Biomat.
Barcelona-based Grifols will use proceedings to reduce debt, which at the end of March stood at 6.2 billion euros (S$9.91 billion).
Grifols shares were up 1.5 per cent in early trading, while benchmark Ibex-35 was down 0.7. The company is valued by the market at 13.5 billion euros.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Motoring tycoon Peter Kwee is back in court: Here are his previous legal battles
Peter Kwee’s Ridley Park bungalow on the market with S$100 million asking price
Demand, tech capabilities position Apac and AI as Skyscanner’s next growth frontiers: CEO Bryan Batista
South-east Asia has lost Nvidia’s best salesman